These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Molecular Modeling Study of c-KIT/PDGFRα Dual Inhibitors for the Treatment of Gastrointestinal Stromal Tumors. Keretsu S; Ghosh S; Cho SJ Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153146 [TBL] [Abstract][Full Text] [Related]
3. Discovery of ( E)- N Liu X; Wang B; Chen C; Qi Z; Zou F; Wang J; Hu C; Wang A; Ge J; Liu Q; Yu K; Hu Z; Jiang Z; Wang W; Wang L; Wang W; Ren T; Bai M; Liu Q; Liu J J Med Chem; 2019 May; 62(10):5006-5024. PubMed ID: 31046271 [TBL] [Abstract][Full Text] [Related]
4. Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations. Hsueh YS; Lin CL; Chiang NJ; Yen CC; Li CF; Shan YS; Ko CH; Shih NY; Wang LM; Chen TS; Chen LT PLoS One; 2013; 8(6):e65762. PubMed ID: 23840364 [TBL] [Abstract][Full Text] [Related]
5. Receptor tyrosine kinase kit and gastrointestinal stromal tumours: an overview. Sartini S; Dario B; Morelli M; Da Settimo F; La Motta C Curr Med Chem; 2011; 18(19):2893-903. PubMed ID: 21651490 [TBL] [Abstract][Full Text] [Related]
7. Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors. Lim KH; Huang MJ; Chen LT; Wang TE; Liu CL; Chang CS; Liu MC; Hsieh RK; Tzen CY Med Oncol; 2008; 25(2):207-13. PubMed ID: 18488160 [TBL] [Abstract][Full Text] [Related]
8. Molecular mechanism of D816X mutation-induced c-Kit activation and -mediated inhibitor resistance in gastrointestinal stromal tumor. Jiang H; Shao W; Wang Y; Xu R; Zhou L; Mu X J Mol Graph Model; 2018 Sep; 84():189-196. PubMed ID: 30015051 [TBL] [Abstract][Full Text] [Related]
9. Molecular basis and management of gastrointestinal stromal tumors. Bayraktar UD; Bayraktar S; Rocha-Lima CM World J Gastroenterol; 2010 Jun; 16(22):2726-34. PubMed ID: 20533592 [TBL] [Abstract][Full Text] [Related]
10. The role of KIT in the management of patients with gastrointestinal stromal tumors. Hornick JL; Fletcher CD Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861 [TBL] [Abstract][Full Text] [Related]
12. Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS). Du J; Wang S; Wang R; Wang SY; Han Q; Xu HT; Yang P; Liu Y Pathol Oncol Res; 2020 Jan; 26(1):91-100. PubMed ID: 31758409 [TBL] [Abstract][Full Text] [Related]
13. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis. Lee JH; Kim Y; Choi JW; Kim YS J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323 [TBL] [Abstract][Full Text] [Related]
14. Identification of a Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia. Lin WH; Wu SY; Yeh TK; Chen CT; Song JS; Shiao HY; Kuo CC; Hsu T; Lu CT; Wang PC; Wu TS; Peng YH; Lin HY; Chen CP; Weng YL; Kung FC; Wu MH; Su YC; Huang KW; Chou LH; Hsueh CC; Yen KJ; Kuo PC; Huang CL; Chen LT; Shih C; Tsai HJ; Jiaang WT J Med Chem; 2019 Dec; 62(24):11135-11150. PubMed ID: 31721578 [TBL] [Abstract][Full Text] [Related]
15. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Lasota J; Miettinen M Histopathology; 2008 Sep; 53(3):245-66. PubMed ID: 18312355 [TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. Liegl B; Kepten I; Le C; Zhu M; Demetri GD; Heinrich MC; Fletcher CD; Corless CL; Fletcher JA J Pathol; 2008 Sep; 216(1):64-74. PubMed ID: 18623623 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875 [TBL] [Abstract][Full Text] [Related]
19. [Molecular mechanism of gastrointestinal stromal tumors and progress in drug research]. Li J Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1316-1320. PubMed ID: 27928806 [TBL] [Abstract][Full Text] [Related]
20. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Debiec-Rychter M; Cools J; Dumez H; Sciot R; Stul M; Mentens N; Vranckx H; Wasag B; Prenen H; Roesel J; Hagemeijer A; Van Oosterom A; Marynen P Gastroenterology; 2005 Feb; 128(2):270-9. PubMed ID: 15685537 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]